Advertisement

Cancer Immunology, Immunotherapy

, Volume 68, Issue 10, pp 1635–1648 | Cite as

Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment

  • Nicholas Osborne
  • Rebecca Sundseth
  • Julian Burks
  • Hong Cao
  • Xunxian Liu
  • Alexander H. Kroemer
  • Lynda Sutton
  • Allen Cato
  • Jill P. SmithEmail author
Original Article

Abstract

Pancreatic cancer has been termed a ‘recalcitrant cancer’ due to its relative resistance to chemotherapy and immunotherapy. This resistance is thought to be due in part to the dense fibrotic tumor microenvironment and lack of tumor infiltrating CD8 + T cells. The gastrointestinal peptide, gastrin, has been shown to stimulate growth of pancreatic cancer by both a paracrine and autocrine mechanism. Interruption of gastrin at the CCK receptor may reduce tumor-associated fibrosis and alter tumor immune cells. Polyclonal Ab Stimulator (PAS) is a vaccine that targets gastrin and has been shown to prolong survival of patients with pancreatic cancer. Here, we report that PAS vaccination monotherapy elicits both a humoral and cellular immune response when used in immune competent mice-bearing pancreatic tumors and that PAS monotherapy produced a marked T-cell activation and influx of CD8 + lymphocytes into pancreatic tumors. Isolated peripheral lymphocytes elicited cytokine release upon re-stimulation with gastrin in vitro demonstrating specificity of immune activation for the target peptide. Combination therapy with PAS and PD-1 Ab activated CD4 −/CD8 − TEMRA cells important in T-cell-mediated tumor death and memory. Tumors of mice treated with PAS (250 μg) or PAS (100 and 250 μg) in combination with a PD-1 Ab were significantly smaller compared to tumors from PBS or PD-1 Ab-treated mice. When PAS was given in combination with PD-1 Ab, tumors had less fibrosis, fewer inhibitory Treg lymphocytes, and fewer tumor-associated macrophages. These findings reveal a novel approach to improve treatment strategies for pancreatic cancer.

Keywords

Tumor microenvironment Vaccine Gamma–delta T cells NKT cells Cellular immunity Gastrin 

Abbreviations

Ab

Antibody

CCK

Cholecystokinin

GI

Gastrointestinal

i.p.

Intraperitoneal

mT3

mT3-2D

PAS

Polyclonal antibody stimulator

PAS100

100 µg Polyclonal antibody stimulator

PAS250

250 µg Polyclonal antibody stimulator

PDAC

Pancreatic ductal adenocarcinoma

s.c.

Subcutaneous

TAMs

Tumor-associated macrophages

TEMRA

Terminally differentiated T cells

TME

Tumor microenvironment

Notes

Acknowledgements

We appreciate the technical support from the staff in the Lombardi Georgetown Comprehensive Cancer Center Core Histology laboratory and Flow cytometry facilities. We also appreciate the staff in the animal care facility. All the investigations in this project were done at Georgetown University School of Medicine in the research laboratory of Dr. Smith, comparative medicine animal facility, and core labs (above) in the Lombardi Georgetown Comprehensive Cancer Center.

Author contributions

JPS, NO, RS, LS and AC conceived and designed research; JPS, JB, HC, and XL performed experiments; JPS, NO, RS, JB, HC, XL, AHK, LS and AC analyzed data; JPS, NO, RS, JB, HC, AHK, LS, and AC interpreted results of experiments; JPS, XL, and HC prepared figures; JPS drafted manuscript; NO, RS, JB, HC, XL, AHK, LS, AC, and JPS edited and revised manuscript; ALL authors approved the content of the final version of manuscript.

Funding

The study was funded in part by a grant from Cancer Advances, Inc. and its subsidiary Vaccicure, and NIH CA051008 to the Georgetown Lombardi Cancer center Core facilities.

Compliance with ethical standards

Conflict of interest

Cato Research, Durham NC has intellectual property rights for PAS. PAS compound was transferred to Georgetown University by a Material Transfer agreement with Vaccicure Limited, Liverpool, UK for this research project. All authors work for Cato Research or Georgetown University.

Ethical approval and ethical standards

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the Georgetown University. The IACUC Protocol Number was 2016-1193 and the protocol approval date was 10/05/2017.

Animal source

C57BL/6 mice were purchased from Charles River Laboratories (Maryland).

Cell line authentication

Murine pancreatic cancer cells, mT3, were a gift from the Tuveson lab (Cold Spring Harbor, NY). Authentication of mT3 murine cells was performed by the investigator that developed the cells [33] and further IMPACT-III testing was performed by IDEXX BioResearch (Columbia, MO) to ensure the cells were pathogen-free.

Supplementary material

262_2019_2398_MOESM1_ESM.pdf (615 kb)
Supplementary material 1 (PDF 614 kb)

References

  1. 1.
    Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617Google Scholar
  2. 2.
    Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371:1039–1049PubMedPubMedCentralGoogle Scholar
  3. 3.
    Falconi M, Mantovani W, Bettini R, Talamini G, Bassi C, Cascinu S, Oliani C, Pederzoli P (2003) Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade? Dig Liver Dis 35:421–427PubMedGoogle Scholar
  4. 4.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30Google Scholar
  5. 5.
    Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA (2011) Stromal biology and therapy in pancreatic cancer. Gut 60:861–868PubMedGoogle Scholar
  6. 6.
    Templeton AW, Brentnall TA (2013) Screening and surgical outcomes of familial pancreatic cancer. Surg Clin N Am 93:629–645PubMedGoogle Scholar
  7. 7.
    Zheng L, Xue J, Jaffee EM, Habtezion A (2013) Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 144:1230–1240PubMedPubMedCentralGoogle Scholar
  8. 8.
    Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA (2012) The pancreas cancer microenvironment. Clin Cancer Res 18:4266–4276PubMedPubMedCentralGoogle Scholar
  9. 9.
    Quante M, Varga J, Wang TC, Greten FR (2013) The gastrointestinal tumor microenvironment. Gastroenterology 145:63–78PubMedPubMedCentralGoogle Scholar
  10. 10.
    Vonderheide RH, Bayne LJ (2013) Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 25:200–205PubMedPubMedCentralGoogle Scholar
  11. 11.
    Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 Ab in patients with advanced cancer. N Engl J Med 366:2455–2465PubMedPubMedCentralGoogle Scholar
  12. 12.
    Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264PubMedPubMedCentralGoogle Scholar
  13. 13.
    Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 Ab MPDL3280A in cancer patients. Nature 515:563–567PubMedPubMedCentralGoogle Scholar
  14. 14.
    Hilmi M, Bartholin L, Neuzillet C (2018) Immune therapies in pancreatic ductal adenocarcinoma: where are we now? World J Gastroenterol 24:2137–2151PubMedPubMedCentralGoogle Scholar
  15. 15.
    Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW (2015) Phase I study of pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Ab) in patients with advanced solid tumors. Clin Cancer Res 21:4286–4293Google Scholar
  16. 16.
    Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA (2010) Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33:828–833PubMedGoogle Scholar
  17. 17.
    Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, Denardo DG, Goedegebuure SP, Linehan DC (2016) Targeting tumour-associated macrophages with CCR17 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17:651–662PubMedPubMedCentralGoogle Scholar
  18. 18.
    Schally AV, Nagy A (2004) Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 15:300–310PubMedGoogle Scholar
  19. 19.
    Smith JP, Fantaskey AP, Liu G, Zagon IS (1995) Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 268:R135–R141PubMedGoogle Scholar
  20. 20.
    Smith JP, Shih A, Wu Y, McLaughlin PJ, Zagon IS (1996) Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. Am J Physiol 270:R1078–R1084PubMedGoogle Scholar
  21. 21.
    Matters GL, Harms JF, McGovern CO, Jayakumar C, Crepin K, Smith ZP, Nelson MC, Stock H, Fenn CW, Kaiser J, Kester M, Smith JP (2009) Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression. Pancreas 38:e151–e161PubMedPubMedCentralGoogle Scholar
  22. 22.
    Smith JP, Liu G, Soundararajan V, McLaughlin PJ, Zagon IS (1994) Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines. Am J Physiol 266:R277–R283PubMedGoogle Scholar
  23. 23.
    Smith JP, Solomon TE (2014) Cholecystokinin and pancreatic cancer: the chicken or the egg? Am J Physiol Gastrointest Liver Physiol 306:G91–G101PubMedGoogle Scholar
  24. 24.
    Zhang JG, Liu JX, Jia XX, Geng J, Yu F, Cong B (2014) Cholecystokinin octapeptide regulates the differentiation and effector cytokine production of CD4 T cells in vitro. Int Immunopharmacol 20:307–315PubMedGoogle Scholar
  25. 25.
    Berna MJ, Seiz O, Nast JF, Benten D, Blaker M, Koch J, Lohse AW, Pace A (2010) CCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production. J Biol Chem 285:38905–38914PubMedPubMedCentralGoogle Scholar
  26. 26.
    Singh P, Owlia A, Espeijo R, Dai B (1995) Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts. Absence of detectable cholecystokinin (CCK)-A and CCK-B receptors. J Biol Chem 270:8429–8438PubMedGoogle Scholar
  27. 27.
    Smith JP, Cooper TK, McGovern CO, Gilius EL, Zhong Q, Liao J, Molinolo AA, Gutkind JS, Matters GL (2014) Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. Pancreas 43:1050–1059PubMedPubMedCentralGoogle Scholar
  28. 28.
    Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint Ab therapy in mice. Cancer Immunol Immunother 67:195–207PubMedGoogle Scholar
  29. 29.
    Watson SA, Michaeli D, Grimes S, Morris TM, Robinson G, Varro A, Justin TA, Hardcastle JD (1996) Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res 56:880–885PubMedGoogle Scholar
  30. 30.
    Watson SA, Morris TM, Varro A, Michaeli D, Smith AM (1999) A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth. Gut 45:812–817PubMedPubMedCentralGoogle Scholar
  31. 31.
    Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van SN, Pounder RE, Caplin ME (2002) Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 20:4225–4231PubMedGoogle Scholar
  32. 32.
    Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulay I, Humphreys J, Whitehead A, Takhar A, Rowlands BJ, Beckingham IJ (2012) An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas 41:374–379PubMedGoogle Scholar
  33. 33.
    Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Ohlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA (2015) Organoid models of human and mouse ductal pancreatic cancer. Cell 160:324–338Google Scholar
  34. 34.
    Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint Ab therapy in mice. Cancer Immunol Immunother 67:195–207PubMedGoogle Scholar
  35. 35.
    Kiyotani K, Chan HT, Nakamura Y (2018) Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci 109:542–549PubMedPubMedCentralGoogle Scholar
  36. 36.
    Nizard M, Roussel H, Diniz MO, Karaki S, Tran T, Voron T, Dransart E, Sandoval F, Riquet M, Rance B, Marcheteau E, Fabre E, Mandavit M, Terme M, Blanc C, Escudie JB, Gibault L, Barthes FLP, Granier C, Ferreira LCS, Badoual C, Johannes L, Tartour E (2017) Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun 8:15221PubMedPubMedCentralGoogle Scholar
  37. 37.
    Willcox BE, Willcox CR (2019) gammadelta TCR ligands: the quest to solve a 500-million-year-old mystery. Nat Immunol 20:121–128PubMedGoogle Scholar
  38. 38.
    Zhao Y, Niu C, Cui J (2018) Gamma-delta (gammadelta) T cells: friend or foe in cancer development? J Transl Med 16:3PubMedPubMedCentralGoogle Scholar
  39. 39.
    Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, Lightfoot S, Benbrook DM, Asch AS, Lang ML, Rao CV (2017) Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras(G12D/+) mice. Immunology 152:36–51PubMedPubMedCentralGoogle Scholar
  40. 40.
    He QF, Xu Y, Li J, Huang ZM, Li XH, Wang X (2019) CD8 + T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy. Brief Funct Genom 18:99–106Google Scholar
  41. 41.
    Lohneis P, Sinn M, Bischoff S, Juhling A, Pelzer U, Wislocka L, Bahra M, Sinn BV, Denkert C, Oettle H, Blaker H, Riess H, Johrens K, Striefler JK (2017) Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer 83:290–301PubMedGoogle Scholar
  42. 42.
    Zhang Z, Zhang C, Li F, Zhang B, Zhang Y (2018) Regulation of memory CD8 + T cell differentiation by MicroRNAs. Cell Physiol Biochem 47:2187–2198PubMedGoogle Scholar
  43. 43.
    Abu Eid R, Razavi G, Mkrtichyan M, Janik J, Khleif SN (2016) Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed. Cancer Immunol Res 4:377–382PubMedGoogle Scholar
  44. 44.
    Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM (2015) Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cance. J Clin Oncol 33:1325–1333PubMedPubMedCentralGoogle Scholar
  45. 45.
    Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN (2011) Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 41:2977–2986PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Cato ResearchDurhamUSA
  2. 2.Department of MedicineGeorgetown UniversityWashingtonUSA
  3. 3.The MedStar Georgetown Transplant InstituteGeorgetown UniversityWashingtonUSA
  4. 4.Cancer Advances, Inc.DurhamUSA

Personalised recommendations